Next Events in Series
The Only Conference Dedicated Exclusively to RNA-Targeted Small Molecules
November 10-12, 2026 | Boston, MA
Unlocking a New Generation of CNS-Targeted Therapies
December 1-3, 2026 | Boston, MA
Korea’s First Industry-Dedicated Forum Driving Innovation in Targeted, Mechanism-Differentiated CNS Therapies
8-10 December, 2026 | Incheon, South Korea
Harnessing Maturing Oligonucleotide Technologies to Unlock Undruggable CNS Targets with Enhanced RNA Chemistry & Innovative Delivery
Oligonucleotide R&D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.
The Annual Oligonucleotides for CNS Summit brings together experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.
This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.
Topic focused, efficient networking and knowledge sharing
Zhenjiu Liu, Principal Scientist, Alnylam
All the talks were highly engaging and interesting. Good mix of science. Vendors were also interesting.
Andrew McCarthy, Oligo Data Science Leader, GSK
The meeting was great for networking, the panelists and presenters were all high caliber and the ensuing discussions very informative
Fay Touti, Senior Director, Asset Discovery, Apellis
Explore the Full 2026 Event Guide
Discover three days of highly technical, data‑driven discussions tackling the most pressing challenges in CNS drug development.
What you’ll find inside:
- Full expert speaker faculty
- Sessions featuring brand‑new data
- Unmissable workshop sessions
- Insight into dedicated networking opportunities
- A breakdown of expected audience
Your definitive guide - share with your team to assess relevance and mobilize internal interest.
2026 Official Partners
Attending Companies Included
Explore Related Events
Join CNS Oligo Experts
Be part of leading discussions with your peers spanning end-to-end development of siRNAs, ASOs, aptamers and more.
Showcase Your Solutions
Align your brand with leading innovators and gain visibility in a space defined by active engagement and strategic partnerships.
Explore the 2026 Agenda
Immerse in fresh data drops, breakthrough approaches in CNS delivery, and a program built to spark conversations.